GSK Prosensa Announce Primary Endpoint Not Met in Phase III Duchenne Muscular Dystrophy Study of Drisapersen

GlaxoSmithKline (GSK) and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrophy (DMD) patients with an amenable mutation, did not meet the primary endpoint of a statistically significant improvement in the 6 Minute Walking Distance (6MWD) test compared to placebo. A total of 186 boys were randomised to this double-blind, placebo-controlled study (DMD114044) and See full press release